AVEO - アベオ・ファ―マシュ―ティカルズ (AVEO Pharmaceuticals Inc.) アベオ・ファ―マシュ―ティカルズ

 AVEOのチャート


 AVEOの企業情報

symbol AVEO
会社名 AVEO Pharmaceuticals Inc (アベオ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アベオ・ファーマシューティカルズ(AVEO Pharmaceuticals Inc.)は癌を治療する会社であり、癌治療法の発見・開発・商業化を中心とする。同社のHuman Responseプラットホームはヒト癌の前臨床モデルを構築する方法であり、同社に癌生物学の洞察を提供し、発見とその癌治療薬の臨床開発で活用されている。平成23年、同社とAstellas Pharma Inc. (Astellas)が提携し、主要製品候補Tivozanibを提供した。Tivozanibはオフターゲット毒性を最小限に抑えながら、血管内皮増殖因子(VEGF)封鎖を最適化するように設計されたすべての3つのVEGF受容体の阻害剤である。平成24年1月、同社は腎細胞癌(RCC)の第一治療法であるグローバルのtivozanib第III相臨床試験のデータ(TIVO-1試験と呼ばれる)を公表した。   アベオ・ファ―マシュ―ティカルズは米国のバイオ医薬品メ―カ―。がんの治療法に注力した新薬の発見、開発、商業化に従事。製品候補には、ERBB3(HER3)受容体をタ―ゲットとする臨床段階モノクロ―ナル抗体である「AV-203」、肝細胞増殖因子の「Ficlatuzumab」、チロシンキナ―ゼ阻害剤の「Tivozanib」などがある。   
本社所在地 One Broadway 14th Floor Cambridge MA 02142 USA
代表者氏名 Michael P. Bailey マイケル・P・ベイリー
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 617-531-2130
設立年月日 37165
市場名 NASDAQ Small Cap
ipoyear 2010年
従業員数 19人
url www.aveooncology.com
nasdaq_url https://www.nasdaq.com/symbol/aveo
adr_tso
EBITDA EBITDA(百万ドル) -24.42000
終値(lastsale) 2.89
時価総額(marketcap) 343997124.83
時価総額 時価総額(百万ドル) 347.47590
売上高 売上高(百万ドル) 6.15500
企業価値(EV) 企業価値(EV)(百万ドル) 348.11690
当期純利益 当期純利益(百万ドル) -27.88200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AVEO Pharmaceuticals Inc. revenues decreased 49% to $1.5M. Net loss decreased 88% to $5M. Revenues reflect Collaboration and licensing revenue decrease of 54% to $1.3M. Lower net loss reflects Change in fair value of PIPE warrant lia increase from $24.4M (expense) to $9.7M (income) Research and Development - Balancing val decrease of 33% to $9.9M (expense) Interest expense.

 AVEOのテクニカル分析


 AVEOのニュース

   Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates  2021/04/02 12:00:21 Benzinga
A slew of drugs, including four new molecular entities, were approved in the month of March. NMEs are drugs that contain active moieties that have never been approved by the Food and Drug Administration previously and are indicators of innovation in drug research. Among the notable approvals that came through in the month were Abecma, the first-ever cell therapy for a type of blood cancer; Fotivda, AVEO Pharmaceuticals, Inc.'s (NASDAQ: AVEO ) oral, next-generation therapy for treating advanced renal cell carcinoma; and KemPharm, Inc.'s (NASDAQ: KMPH ) Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Here are the key FDA approvals scheduled for April. Acadia Hopes Against Hope to Get Label Expansion Psychosis Drug Company: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Type of Application: supplemental new drug application Candidate: pimavanserin Indication: dementia Date: April 3 Pimavanserin, which is marketed under the trade name Nuplazid, has already been approved by the FDA for the treatment of hallucinations associated with Parkinson's disease psychosis.
   AVEO Announces Proposed Public Offering of Common Stock  2021/03/22 20:01:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. All of the shares in the offering are to be sold by AVEO. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering
   AVEO Pharmaceuticals Confused? Buy or Sell in volatile market - Analyst report Stock market Insights & financial analysis  2021/03/15 19:03:00 Stock Market Daily
AVEO Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   AVEO Pharmaceuticals, CANbridge AV-203 Licensing Deal Axed, AVEO Regains Ex-North American Rights  2021/03/15 10:41:00 Benzinga
AVEO Pharmaceuticals Inc’s (NASDAQ: AVEO) brief positive news of getting FDA approval for Tivozanib in relapsed kidney cancer this …
   The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs  2021/03/12 12:36:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 11) Affimed N.V. (NASDAQ: AFMD ) AngioDynamics, Inc. (NASDAQ: ANGO ) Apyx Medical Corporation (NASDAQ: APYX ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Axonics Modulation Technologies, Inc. (NASDAQ: AXNX ) BioAtla, Inc. (NASDAQ: BCAB ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Entera Bio Ltd. (NASDAQ: ENTX ) ( announced positive Phase 2 biomarker data for osteoarthritis drug) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Inari Medical, Inc. (NASDAQ: NARI ) Jounce Therapeutics, Inc. (NASDAQ: JNCE ) Longeveron Inc. (NASDAQ: LGVN ) (announced FDA granting expanded access approval for its investigational cell therapy Lomecel-B to a pediatric patient with hypoplastic left heart syndrome) Magenta Therapeutics, Inc. (NASDAQ: MGTA ) Nuvation Bio Inc. (NASDAQ: NUVB )(announced orphan drug designation for NUV-422 in treating malignant gliomas) Renalytix AI plc (NASDAQ: RNLX ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Surmodics, Inc. (NASDAQ: SRDX ) Verrica Pharmaceuticals Inc. (NASDAQ: VRCA ) Down In The Dumps None of the NYSE- and Nasdaq-listed biotech/diagnostic shares hit 52-week lows Thursday.
   Hot Stock Evaluation: Ocugen, Inc. (NASDAQ:OCGN), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Stocks Equity  2021/01/29 21:05:31 Stock Equity
Ocugen, Inc. (NASDAQ:OCGN) with the stream of -1.68% also noticed, India AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) encountered a rapid change of 2.81% in the last hour of Friday’s trading session. Ocugen, …
   Ex-CFO of biotech company Aveo loses SEC fraud verdict appeal  2021/01/22 21:22:04 Reuters
A federal appeals court on Friday upheld a jury's verdict finding that Aveo Pharmaceuticals Inc's ex-chief financial officer misled investors about the prospects for regulatory approval of its flagship drug under development.
   Global Small Molecule Targeted Cancer Therapy Market 2021:Emerging Opportunities, Revenue Analysis and Growth Projections by Bayer AG; GlaxoSmithKline plc.; AstraZeneca; AVEO Pharmaceuticals, Inc.; Johnson & Johnson Services  2021/01/21 09:15:10 OpenPR
Data Bridge Market research released a new market study on Small Molecule Targeted Cancer Therapy with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In Small Molecule Targeted Cancer
   AVEO Oncology Highlights Recent Progress and 2021 Outlook  2021/01/07 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook. “We remain keenly focused on building out our commercial team ahead of the potential U.S. launch of tivozanib as a treatment for relapsed or refractory renal cell carcinoma (RCC), including the addition of Dr. Corinne Epperly to our Board of Directors,” said Michael Bailey, president and chief executive officer of AVEO. “If approved, we believe tivozanib has the potential t
   AVEO Oncology Announces Participation at Two Upcoming Investor Conferences  2021/01/06 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: H.C. Wainwright Virtual BioConnect Conference Date: Monday, January 11 – Thursday, January 14 B. Riley Virtual Oncology Investor Conference Date: Wednesday, January 20 Time: 1:30 PM Eastern Time A replay of the pre-recorded H.C. Wainwright presentation can be accessed on Monday, January 11, 2021 i
   AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference  2020/11/10 12:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date. About AVEO Pharmaceut
   AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/09 21:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update. “In advance of the Food and Drug Administration’s (FDA) March 31, 2021 Prescription Drug User Fee Act (PDUFA) target action date for our tivozanib New Drug Application, we are actively building out AVEO’s U.S. commercial infrastructure to support the FDA-pending U.S. launch of tivozanib in relapsed or refractory renal cell carcinom
   AVEO Pharmaceuticals (NASDAQ:AVEO) Cut to “Hold” at Zacks Investment Research  2020/10/22 04:03:01 Dispatch Tribunal
Zacks Investment Research downgraded shares of AVEO Pharmaceuticals (NASDAQ:AVEO) from a buy rating to a hold rating in a report released on Monday, Zacks.com reports. According to Zacks, “AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed […]
   AVEO Pharmaceuticals (NASDAQ:AVEO) Rating Lowered to Hold at Zacks Investment Research  2020/10/21 06:36:48 Zolmax News
AVEO Pharmaceuticals (NASDAQ:AVEO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, “AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against […]
   AVEO Pharmaceuticals (NASDAQ:AVEO) Lowered to “Hold” at Zacks Investment Research  2020/10/20 01:26:42 Daily Political
Zacks Investment Research downgraded shares of AVEO Pharmaceuticals (NASDAQ:AVEO) from a buy rating to a hold rating in a report released on Monday morning, Zacks.com reports. According to Zacks, “AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アベオ・ファ―マシュ―ティカルズ AVEO AVEO Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)